ADC: ORR Cannot Serve as a Surrogate Endpoint!
▲ Multiple benefits are coming, click to make an appointment Surrogate endpoints (such as PFS, ORR) are significant in clinical trials for tumors, as they can accelerate the drug approval process, allowing patients to receive effective treatments more quickly.PFS has long been considered an effective surrogate endpoint for OS in chemotherapy trials for advanced solid … Read more
